Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status - Université Toulouse III - Paul Sabatier - Toulouse INP Accéder directement au contenu
Article Dans Une Revue Endocrine Connections Année : 2022

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status

Résumé

Introduction Mutations in PTPN11 are associated with Noonan syndrome (NS). Although the effectiveness of growth hormone therapy (GHT) in treating short stature due to NS has been previously demonstrated, the effect of PTPN11 mutation status on the long-term outcomes of GHT remains to be elucidated. Methods This analysis included pooled data from the observational American Norditropin Studies: Web-Enabled Research Program (NCT01009905) and the randomized, double-blinded GHLIQUID-4020 clinical trial (NCT01927861). Pediatric patients with clinically diagnosed NS and confirmed PTPN11 mutation status were eligible for inclusion. The effectiveness analysis included patients who were GHT-naïve and pre-pubertal at GHT start. Growth outcomes and safety were assessed over 4 years of GHT (Norditropin®, Novo Nordisk A/S). Results A total of 69 patients were included in the effectiveness analysis (71% PTPN11 positive). The proportion of females was 32.7 and 30.0% in PTPN11 -positive and negative patients, respectively, and mean age at GHT start was 6.4 years in both groups. Using general population reference data, after 4 years of GHT, the mean ( s.d. ) height SD score (HSDS) was −1.9 (1.1) and −1.7 (0.8) for PTPN11 -positive and PTPN11 -negative patients, respectively, with no statistical difference observed between groups. The mean ( s.d. ) change in HSDS at 4 years was +1.3 (0.8) in PTPN11 -positive patients and +1.5 (0.7) in PTPN11- negative patients (no significant differences between groups). Safety findings were consistent with previous analyses. Conclusions GHT resulted in improved growth outcomes over 4 years in GHT-naïve, pre-pubertal NS patients, irrespective of PTPN11 mutation status.
Fichier principal
Vignette du fichier
JORGE.pdf (1.48 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04577280 , version 1 (16-05-2024)

Licence

Identifiants

Citer

Alexander a L Jorge, Thomas Edouard, Mohamad Maghnie, Alberto Pietropoli, Nicky Kelepouris, et al.. Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status. Endocrine Connections, 2022, 11 (4), pp.e210615. ⟨10.1530/EC-21-0615⟩. ⟨hal-04577280⟩
17 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More